| Budget Amount *help |
¥88,400,000 (Direct Cost: ¥68,000,000、Indirect Cost: ¥20,400,000)
Fiscal Year 2014: ¥15,470,000 (Direct Cost: ¥11,900,000、Indirect Cost: ¥3,570,000)
Fiscal Year 2013: ¥16,250,000 (Direct Cost: ¥12,500,000、Indirect Cost: ¥3,750,000)
Fiscal Year 2012: ¥16,900,000 (Direct Cost: ¥13,000,000、Indirect Cost: ¥3,900,000)
Fiscal Year 2011: ¥16,770,000 (Direct Cost: ¥12,900,000、Indirect Cost: ¥3,870,000)
Fiscal Year 2010: ¥23,010,000 (Direct Cost: ¥17,700,000、Indirect Cost: ¥5,310,000)
|
|---|
| Outline of Final Research Achievements |
Adipocytes overexpressed S100A8 in early phase of obesity. Anti-S100A8 antibody suppressed dynamic movement of macrophage in adipose tissue of obesity. Exogenous adiponectin accumulated mainly to stromal vascular fraction (SVF) of adipose tissue and aorta without ectopic expression. Adipose SVF adiponecitn increased in obesity. Adiponectin covered surface of endothelial cells in aorta, and was additionally detected on smooth muscle cells in atherosclerotic lesion. Binding of adiponectin to aorta required T-cadherin. Also, concentration of adiponectin binding to C1q was elevated in spite of hypoadiponectinemia in patients with acute coronary syndrome. These data suggest adiponectin belongs to a new category of endocrine factors. Type 2 diabetics with metabolic syndrome often had polyvascular lesions by ultrasonography and abnormalities of adipocytokines. Estimation of arteriosclerosis and visceral fat are potentially useful for the management of these patients.
|
